It’s been an announcement-packed JPMorgan Healthcare Conference in San Francisco this week!

A number of testing companies had exciting business announcements including Genomic Health (which reached the expected profitability in 2017), Foundation Medicine(which may boast a higher than expected fourth quarter revenue), Invitae (which exceeded its annual projected testing volume), Myriad Genetics (which saw a volume gain for its hereditary cancer testing), Guardant Health (which plans to submit its Guardant360IVD liquid biopsy assay for FDA approval in 2018), 10x Genomics (which recognized a healthy $71M revenue in 2017), Twist Bioscience (which shipped more than 150K genes to its customers in 2017), and Edico Genome (which was selected by Genomics England to use the DRAGEN pipeline to re-analyze 5000 whole genomes).

Then, of course, there were the Illumina and Thermo Fisher Scientific announcements around the launch of new sequencing instruments. Illumina launched its $20,000 desktop iSeq 100 sequencer that allows researchers to study viruses, bacteria, and other microbes. Thermo Fisher launched the semiconductor sequencing technology-based Ion GeneStudio S5 Prime and the Ion GeneStudio S5 Plus for sequencing in oncology, noninvasive prenatal testing, and applied markets. Last but not least, the new Illumina library prep partnership with Thermo Fisher enables Illumina to sell Ion AmpliSeq technology to researchers who conduct studies on Illumina’s NGS platform.

In one of the largest efforts to create human genetic data to identify “many more” actionable genes, a consortium of pharmaceutical companies led by Regeneron will sequence the genes of 500,000 volunteers from the United Kingdom, the data from which will be broadly accessible by 2020. Specifically, Regeneron will handle all the sequencing and AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen, and Pfizer will each contribute $10 million to create this data that will largely focus on exomes.

These exciting New Year developments are a great lead in to our upcoming 13th Personalized Medicine World Conference taking place in 10 days, January 22-24, in Silicon Valley.

The upcoming PMWC agenda focuses on the relevance and developments of next-generation sequencing, new applications in clinical diagnostics, and feature a number of sessions dedicated to artificial intelligence, gene therapy, immunotherapy, and more. The speaker lineup includes those from commercial companies that are active in the sequence systems space with dedicated sessions covering:

In addition, conference attendees will hear from a broad representation of organizations that are building genetic testing and diagnostic solutions (Guardant Health, Foundation Medicine, Invitae, Inflammatix, iNDx Technology, Quest Diagnostics, CardioDx, UCSF, Broad Institute, Veracyte, Viviphi Ltd, and many more).

Hope to see you all at the upcoming conference where you can witness how some of these recent announcements translate into action in the clinical sector and precision medicine in particular.

Interview with Honoree Mary Relling, PMWC Duke 2018 Luminary Honoree

Q: Why is preemptive pharmacogenetics testing important in the context of personalized medicine?

A: We estimated that pharmacogenetic test results can impact the use of nearly 100 drugs, accounting for up to 18% of current prescriptions. Therefore, having pharmacogenetic test results already “in hand” at the time of prescribing will be more convenient for patients and physicians compared to performing as needed, one gene-at-a-time testing, which will be slower and more expensive.

Read More

Interview with Eric Perakslis from Datavant

Q: What need is Datavant addressing?

A: While the volume of health data grows precipitously year over year, our ability to make use of that data is not keeping pace. There are many aspects to the inherent challenges and opportunities of this data explosion but of particular concern is the increased fragmentation.

Read More

All of Us Research Program Aims to Create Diverse Research Data Resource

In the age of big DNA data, it is important to remember that accumulating large amounts of data is not enough. Equally important is keeping the DNA data that participants provide as diverse as possible to allow us to generate answers to questions about how different variables impact people differently.

Read More

Interview with Philip Parks from Exact Sciences Corporation

Q: What need is Exact Sciences Corporation addressing?

A: Exact Sciences’ mission is to improve patient outcomes through the early detection of cancer. We are especially focused on developing highly accurate, minimally invasive screening tests and technologies.

Read More

Interview with Mike Nall from Biocept, Inc.

Q: What need is Biocept, Inc addressing?

A: Physicians are not receiving all the genomic information needed for precision medicine therapeutic decision making so some patients potentially miss out on targeted therapies that could save or extend their lives.

Read More

Interview with Michael Pellini from Section 32

Q: How do you select startup companies you invest in? What are values you are looking for both in the companies and the leadership teams?

A: This answer is more of a philosophical one rather than a simple listing of ingredients, even though the latter might be easier or more reassuring for an entrepreneur to digest.

Read More

Jeff Gordon, The “Father of the Microbiome” On The Promises and Challenges of the Microbiome in Precision Medicine

The microbiome significantly impacts human health, playing a crucial role in maintaining health and preventing disease. It influences endocrinology, physiology, and even neurology, altering the outcome of many different disease states, and it has been shown to augment drug responses and tolerance. In parallel to your normal microbiota, headlining pathogens are grabbing our attention, as we seem to face a major epidemic or viral outbreak of some sort each year, whether it is Zika, Ebola, or the Coronavirus MERS-CoV.

Read More

Q&A with Jeff Balser, Dean of Vanderbilt University School of Medicine, President & CEO VUMC

Q: What is your vision for personalized care?

A: While the term “personalized care” has become popular contemporary with the maturation of genomic medicine, it is clear that the entire context of care – including social, behavioral, and environmental factors – drives the outcomes we are hoping to achieve.

Read More

Q&A with All of Us Research Program Deputy Director Stephanie Devaney, Ph.D.

Q1a: You are the Deputy Director of the All of Us Research Program. What is your role as the deputy director and why is this initiative so important?

A: As deputy director, my primary role is to work closely with the All of Us Director Eric Dishman in guiding the program from concept to reality. Our vision is to enable a healthier future for all of us by building a data resource that scientists can use to speed up research and the development of individualized approaches to prevention and treatment.

Read More

Interview with Honoree Jeffrey Gordon, PMWC 2018 Duke Luminary Honoree

Q: Why is the microbiome so important in the context of precision medicine?

A: We can’t ignore a part of our body that is composed of tens and tens of trillions cells, albeit microbial – a population that collectively contains at least two orders of magnitude more genes than in our Homo sapiens genome, endows us with attributes and capabilities that we have not had to evolve on our own, and contributes to our intra- and interpersonal biological variations as well as health status.

Read More

Call to the Health Care Community to Execute on Next Steps for a Wider Adoption and Implementation of Precision Medicine

The recent Facebook data breach, genetic data sleuthing by the FBI that led to the Golden State Killer, and the soon-to-be-implemented European General Data Protection Regulation (GDPR), has put data privacy and security front and center.

Read More

Data Privacy, the Security, And Ownership

The recent Facebook data breach, genetic data sleuthing by the FBI that led to the Golden State Killer, and the soon-to-be-implemented European General Data Protection Regulation (GDPR), has put data privacy and security front and center.

Read More

Q&A with Jason Crites from IBM & Piers Nash from Health2047 Speaking at PMWC 2018 Michigan in June

Q: What need is IBM and Health2047 addressing in the healthcare/life sciences sector?

Jason (IBM): The industry is undergoing a significant transformation as reimbursement shifts from fee-for-service to value-based outcomes in the face of regulatory uncertainty.

Read More

Dr. Francis Collins of NIH at June PMWC Michigan- Launch of Nationwide Participation Enrollment!

This past Sunday—May 6, 2018—the program reached a major milestone with the start of the nationwide participation enrollment! The All of Us Research Program, part of the Precision Medicine Initiative that was famously announced by President Barack Obama at the 2015 State of the Union address, aims to enroll a total of 1 million Americans.

Read More

Meet Dr. Gil Omenn, Director of the University of Michigan Center for Computational Medicine & Bioinformatics on June 6th at PMWC 2018 Michigan

Q: What are the objectives of the Human Proteome Project and what are some of the recent breakthrough discoveries?

The HUPO Human Proteome Project has two overarching goals: (1) to complete the protein parts list, with at least one protein product from each of the ~20,000 protein-coding genes along with sequence variants, splice variants, and post-translational modifications, with characterization of their functions;…

Read More
University of Michigan

The Precision Medicine World Conference (PMWC), held annually in Silicon Valley, is coming back to North Carolina for its 2nd Conference back at Duke University on September 24-25, 2018.

PMWC 2018 Duke, the 15th installment of the conference, will spotlight the explosion of biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

 

  • Track 1 will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • Digital Phenotyping
    • Precision Public Health
    • Pharmacogenomics
    • The Microbiome
    • Rare Disease Diagnosis
    • Digital Health/Health and Wellness
    • Early Days of Life Sequencing
    • Diversity in Precision Medicine
    • Resilience
    • AI and Machine Learning
    • Gene Editing
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Point-of Care Dx Platform
    • FDA Efforts to Accelerate PM
    • Implementation into Health Care Delivery
    • Next Gen. Workforce of PM
    • Immunotherapy
    • Robust Clinical Decision Support Tools
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Neoantigens
    • Emerging Technologies In PM

The Precision Medicine World Conference (PMWC), held annually in Silicon Valley, is coming back to North Carolina for its 2nd Conference back at Duke University on September 24-25, 2018.

PMWC 2018 Duke, the 15th installment of the conference, will spotlight the explosion of biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

 

    • Track 1 will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • Digital Phenotyping
      • Precision Public Health
      • Pharmacogenomics
      • The Microbiome
      • Rare Disease Diagnosis
      • Digital Health/Health and Wellness
      • Early Days of Life Sequencing
      • Diversity in Precision Medicine
      • Resilience
      • AI and Machine Learning
      • Gene Editing
      • Large Scale Bio-data Resources
        to Support Drug Development (PPPs)
      • Point-of Care Dx Platform
      • FDA Efforts to Accelerate PM
      • Implementation into Health Care Delivery
      • Next Gen. Workforce of PM
      • Immunotherapy
      • Robust Clinical Decision Support Tools
      • Creating Clinical Value with Liquid Biopsy
        ctDNA, etc.
      • Neoantigens
      • Emerging Technologies In PM
  • Track 2- PMWC 2018 Duke Showcase, will enable 15-minute company presentations on latest novel technologies. Apply to present here.
big data diagnostics session

Clinical Dx Showcase

crispr showcase

Emerging Therapeutics Showcase

NGS Showcase

Genomic Profiling Showcase

AI Showcase Session Image

AI and Data Sciences Showcase

  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 500+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine

pmwc-newsletter-img

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To recieve the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!